A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease

The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18 months (76 weeks), with a minimum treatment period of 9 months. Amyloid PET scans will be conducted at screening, 9, and 18 months in Part 1. Participants who are at or below 11 CL at screening or reach complete amyloid plaque clearance as measured by florbetapir F18 PET (defined as ≤11 CL) at 9 months will initiate Part 2. Participants who are ≤11 CL at screening may delay their entry into Part 2 for up to 6 months at the discretion of the Investigator. All remaining participants will start Part 2 after completing 18 months (76 weeks) in Part 1 independent of amyloid results. Non-carriers will receive placebo in both Parts 1 and 2.
In Part 2, study participants who are mutation carriers will be randomized 1:1:1:1 in a full factorial design to receive either RG6289 + placebo-donanemab (RG6289 alone group), donanemab + placebo-RG6289 (donanemab alone group), the combination of RG6289 and donanemab (combination group), or placebo-RG6289 and placebo-donanemab (placebo group). All non-carriers will be assigned to the placebo group. CDR-GS at the end of Part 1 and the amyloid level using the last completed amyloid PET scan in Part 1 will be used for stratification. All study participants will participate in a double-dummy design for the duration of Part 2 receiving both an intravenous (IV) infusion at the required interval for the donanemab or matching placebo as well as a daily oral treatment of RG6289 or matching placebo.
An exploratory outcome of Part 1 is a comparison of the amyloid clearance between this ADAD cohort and historical controls using propensity score matching. The primary outcome in Part 2 is change from the start of Part 2 through the end of Part 2 in brain amyloid load in PSEN1 E280A mutation carriers as measured by amyloid PET imaging. Other endpoints will include fluid and imaging biomarkers and measures of cognition and functioning. The maximum study duration for any individual participant will be 3 years, not including the screening or follow-up periods

Start Date01 Dec 2025

Sponsor / Collaborator

Banner Health

[+2]

NCT06911944

/ Not yet recruitingPhase 4IIT

A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Donanemab in Adults With Down Syndrome

The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
The main questions it aims to answer are: Does donanemab reduce amyloid in the brain? Is donanemab safe and well-tolerated in people with Down syndrome? Researchers will compare donanemab to a placebo (a look-alike substance that contains no drug) to see if donanemab works to reduce levels of amyloid in the brain.
Participants in the study will be 35-50 years old and will be in the study for 12 months. Participants will then stay in the study for an additional 12 months in an long-term extension where all participants will receive donanemab. Participants who had a reduction in amyloid (measured by amyloid brain scan) by the end of the first 12 months will receive placebo for the long-term extension, while participants who did not have an amyloid reduction will receive study donanemab for the long-term extension. Everyone (participants and study staff) will remain blinded to treatment for the duration of the study.
Participants will:
* Have intravenous (IV) infusions of donanemab (or placebo) every 4 weeks
* Visit the clinic once every other month for checkups and tests. These tests will include brain scans (magnetic resonance imaging [MRI] and positron emission tomography [PET] ), blood draws and memory tests.
* Have a study partner who who can provide information about the participant and can join participant for some of the study visits.

Start Date01 Jun 2025

Sponsor / Collaborator

University of Southern California

[+3]

NCT06566170

/ RecruitingNot Applicable

Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.

Start Date07 Oct 2024

Sponsor / Collaborator

Eli Lilly & Co.

100 Clinical Results associated with Donanemab-AZBT

100 Translational Medicine associated with Donanemab-AZBT

100 Patents (Medical) associated with Donanemab-AZBT

203

Literatures (Medical) associated with Donanemab-AZBT

01 Feb 2026·Neural Regeneration Research

Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease

Article

Author: Guo, Wanshu ; Sha, Sha ; Ren, Lina ; Qu, Le ; Li, Ying ; Cao, Yunpeng ; Wang, Yan ; Xing, Xiaona

Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer’s disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline. Currently, active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer’s disease and other transgenic animal models, attracting considerable attention. However, the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab. This review first discusses the advancements in the pathogenesis of Alzheimer’s disease and active and passive immunotherapies targeting amyloid-beta and tau proteins. Furthermore, it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects. Although some antibodies have shown promise in patients with mild Alzheimer’s disease, substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer’s disease.

01 Sep 2025·Value in Health Regional Issues

Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil

Article

Author: Moriguti, Julio Cesar ; Price, Price Udo ; Pereira, Leonardo Regis Leira ; Heggie, Robert

OBJECTIVES:

Alzheimer disease (AD) is a worsening neurodegenerative disorder and the leading cause of dementia, accounting for 60% to 70% of cases. It contributes significantly to disability, caregiver reliance, and is the eighth leading cause of death. AD is one of the most expensive diseases to treat, creating an economic burden for the healthcare system and families of patients. Dementia care costs in Brazil are projected to reach $49.2 billion by 2030, $63.5 billion by 2040, and $77.3 billion by 2050. This study evaluated the cost-effectiveness of acetylcholinesterase inhibitors (standard of care [SoC]) in slowing disease progression compared with no pharmacological therapy (best supportive care [BSC]), lecanemab, and donanemab in mild AD patients.

METHODS:

We developed a decision-analytic model to simulate AD progression, using cost and health utility data specific to Brazil, supplemented with data from the literature when necessary. The model covers a 20-year horizon from both the Brazilian national healthcare system and societal perspectives. Costs and quality-adjusted life years (QALYs) were discounted at 3.5% per year to reflect their present value. Costs in local currencies were converted to US dollars (US$) and inflation-adjusted to 2024 values.

RESULTS:

In the base-case analysis from the healthcare perspective, SoC was more clinically effective than BSC with a cost per QALY of $5211. For lecanemab versus SoC, the cost per QALY gained was $2 098 225, whereas donanemab versus lecanemab was $1 460 400.

CONCLUSIONS:

The SoC is a cost-effective pharmacological intervention for AD, offering the lowest cost per QALY gains over a 20-year period.

01 Jul 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

New drugs approved by the NMPA in 2024: Synthesis and clinical applications

Review

Author: Yuan, Lin ; Gong, Zheng ; Zhao, Xinxin ; Yuan, Ye ; Geng, Jin ; Li, Mengqi

In 2024, the National Medical Products Administration (NMPA) approved 46 Class 1 or 1.1 innovative drugs, including 7 imported drugs and 39 domestically developed drugs, marking a new record in China's pharmaceutical innovation. These approvals encompassed 23 chemical drugs, 20 biological products, and 3 traditional Chinese medicines or natural products, demonstrating continuous growth in innovative drug development. Compared to 16 approvals in 2020 and the surge in 2021, when approvals equaled the total of the previous four years, the trend of increased approvals has resumed since 2024. Therapeutically, oncology drugs remained the dominant category in 2024, comprising 50 % (23/46) of approvals. Gastrointestinal and metabolic drugs, accounting for 13.04 % (6/46), surpassed other categories to rank second, followed by neurological drugs (8.7 %, 4/46). Anti-infectives, miscellaneous drugs, and traditional Chinese medicines each contributed three approvals (7.5 % each). Regulatory advancements played a significant role, with 18 drugs (39.13 %) approved via priority reviews, emergency reviews, or conditional approvals. This group included 9 chemical drugs and 9 biological products, with notable breakthrough therapies such as taletrectinib, lutetium monoclonal antibodies, and donanemab receiving special recognition. The 2024 data reflect China's growing capabilities in drug innovation and its commitment to addressing critical medical needs through accelerated regulatory pathways.

509

News (Medical) associated with Donanemab-AZBT

18 Jun 2025

·www.biospace.com

More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech

iStock, Michael Vi On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the company is leveraging its unprecedented success in obesity to support young biotechs. Eli Lilly is on something of a tear, aiming to prove with Tuesday’s $1.3 billion acquisition of Verve Therapeutics that it’s more than just a cardio-metabolic and neuroscience company. The Indianapolis-based pharma is most famous for its obesity and type 2 diabetes drugs, Zepbound and Mounjaro, and Alzheimer’s medicine Kisunla. But in addition to these two areas, along with oncology and immunology, Lilly also has an unofficial fifth focus, Julie Gilmore, vice president and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management, told BioSpace at BIO2025 on Tuesday. That bonus focus is platforms and genetic medicine, which “can span all four of those core therapeutic areas,” Gilmore explained. In the case of this week’s Verve purchase, Lilly is gaining gene therapies that target cardiovascular disease. “This is the whole intent of what we’re doing, finding exciting science,” said Gilmore, who runs Lilly’s incubator program. “[Verve is] a great example.” One might think that Lilly should be content with its current portfolio. The company’s $45 billion in 2024 revenue was good enough for 9 th place among its top 20 pharma peers, and a 32% bump over the $34.1 billion for 2023. Lilly overtook its closest obesity competitor, Novo Nordisk, whose $42.1 billion was good for 11 th place. Julie Gilmore, vice president and global head of Lilly Gateway Labs and Catalyze360 Portfolio Management But Lilly isn’t resting on its laurels with Zepbound and Kisunla, or even relying only on its current key therapeutic areas. In fact, Gilmore said, only about 50% of its incubator companies are focused on these spaces. “At least half of our companies are doing things outside of our core strategy,” she said. “So they may be pursuing different therapeutic areas, different targets, different disease states, different modalities.” This is with an eye toward possibly branching out in the future, she added. “What is the greatest emerging science and what can we do to be a part of that and learn?” One emerging therapeutic area Lilly has already identified through the incubators is healthspan and longevity, which Gilmore said is “kind of adjacent” to the company’s current internal efforts. She questioned, however, whether it’s a space on its own. “I don’t know that we see that, but we do see it playing out in each of our areas of interest, and maybe even beyond our core therapeutic areas,” she said. “It’s something we’re definitely keeping an eye on.” She added that there are lots of new companies forming around longevity science. One of these companies, the aptly named Life Biosciences, was also at BIO2025. Chief Scientific Officer Sharon Rosenzweig-Lipson wouldn’t wager a guess as to the million-dollar question: How long could human beings actually live? But she did tell BioSpace , “We’re focused on reversing and treating age-related diseases, with hopefully a side effect of longevity. And then we’ll see.” Back at Lilly, Gilmore said incubator companies are selected based on “cutting edge science” and the potential for a symbiotic relationship. “Does Lilly have something we can offer them, do we have history, expertise, capabilities that we could apply to help them move forward?” In the current marketplace, Gilmore said she has “such admiration for those out there, fighting the good fight right now, because it’s not easy. . . . We’re stepping in to say, okay, where can a company like Lilly help while you’re fundraising?” Gilmore has been at Lilly for most of her career, and one thing she is proud of is how the company is leveraging its success and learnings in the obesity space to support biotech. “It’s not just going back into our own portfolio. We’re actually trying to use that success to support others. And that’s been a lot of fun, kind of a proud moment to be able to do that.”

Acquisition

12 Jun 2025

·www.einpresswire.com

Interim report: Nuravax's Alzheimer’s vaccine AV-1959R found safe, immunogenic in all healthy volunteers.

Nuravax’s Alzheimer’s vaccine AV-1959R is safe, triggered strong immune responses in all Phase 1 trial participants, showing promise for disease prevention. IRVINE, CA, UNITED STATES, June 12, 2025 / EINPresswire.com / -- Nuravax Inc. , a biotechnology company specializing in active immunotherapy for neurodegenerative disorders, received promising preliminary clinical data from its placebo-controlled, double-blind Phase 1 trial of AV-1959R . The amyloid-beta (Aβ) adjuvanted vaccine is based on its universal MultiTEP platform technology, licensed from the non-profit Institute for Molecular Medicine (IMM). No serious adverse events (SAEs) have been reported, and MRI scans show no signs of ARIA-E (edema) or ARIA-H (microhemorrhages) in all vaccinated and placebo people. “Initial results on immunogenicity are highly encouraging, with very strong antibody responses meeting our expectations based on the study's active-to-placebo allocation, said Roman Kniazev, CEO of Nuravax. “Achieving a 100% responder rate and an excellent safety profile so far in this Phase 1 trial is a significant milestone. This safe and immunogenic vaccine has full potential in Phase 2 to demonstrate its ability to prevent the onset of Alzheimer’s disease in vaccinated cognitively unimpaired individuals who are at risk for the disease.” This initial human data from a MultiTEP ® -based AV-1959R vaccine highlights the platform’s strong potential, which also supports other Nuravax’s preventive vaccine candidates for neurodegenerative disorders currently under development. The MultiTEP technology, licensed from IMM, is designed to activate non-harmful T helper cell responses that trigger humoral immunity and stimulate the production of antibodies. These antibodies help reduce or prevent the accumulation of aggregated Aβ, which initiates Alzheimer's disease pathophysiology. “Preclinical results and clinical data with monoclonal antibodies, Leqembi ® , Kisunla™ suggest that a safe and immunogenic Aβ vaccine may inhibit the accumulation of pathological amyloid, potentially delaying the onset of Alzheimer’s in cognitively unimpaired individuals at risk of disease,” said Dr. Michael Agadjanyan, VP of IMM. "These early findings suggest that after the completion of Nuravax’s Phase 1 trial, this AV-1959R vaccine would be a prime candidate for primary and secondary preventive therapy for individuals at risk of Alzheimer’s.” These encouraging early results also reflect the impact of a carefully developed manufacturing strategy that preserves the antigen’s structure. This process is critical for inducing high-titer, target-specific, and functional antibodies, an essential factor in achieving effective immune engagement in the context of Alzheimer’s disease prevention. About Nuravax Nuravax Inc. is a clinical-stage biotech company developing and advancing immunotherapeutic vaccines for neurodegenerative diseases, including Alzheimer's, Parkinson's, TBI, and CTE. Focused on early intervention, Nuravax aims to alter disease progression before irreversible damage occurs. In addition to AV-1959R, the company’s portfolio of Alzheimer’s prevention vaccines includes AV-1980R and Duvax. About IMM The Institute for Molecular Medicine (IMM) is a non-profit research organization dedicated to understanding, preventing, and curing chronic human diseases, with a focus on neurodegeneration. IMM is advancing MultiTEP — a universal vaccine platform technology that enables the development of diverse vaccine formats, including DNA, RNA, and recombinant protein-based designs. Victoria Zavyalova V Startup Agency vic@vstargency.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

VaccineClinical ResultPhase 1ImmunotherapyPhase 2

26 May 2025

·www.echemi.com

$470 Million Acquisition Signals Fierce Race in Alzheimer’s Drug Development

Sanofi has struck a $470 million deal to acquire Vigil Neuroscience, a bold move aimed at securing VG-3927, an investigational oral small molecule designed to target TREM2—a key immune receptor linked to Alzheimer’s disease. This acquisition, expected to close in Q3 2025, also includes a $2 contingent value right (CVR) per share tied to VG-3927’s first commercial sale. VG-3927, which enables once-daily dosing, is on track to enter Phase II clinical trials later this year. Earlier Phase I data revealed a dose-dependent drop of up to 50% in soluble TREM2 levels in cerebrospinal fluid, signaling promising biological activity. As competition heats up, giants like Pfizer, AbbVie, Eisai, and Eli Lilly are advancing amyloid-targeted therapies already approved by the FDA, including Lecanemab and Donanemab. At the same time, companies such as Bristol Myers Squibb, Roche, and Sanofi are bolstering their neuro pipelines through aggressive M&A activity. In parallel, BioArctic recently secured a $1 billion+ licensing deal with BMS for next-gen amyloid antibodies using BrainTransporter™ tech, while AbbVie’s acquisition of Aliada focuses on BBB-penetrating therapies like ALIA-1758. Genentech, under Roche, is also advancing gene-silencing therapies targeting Tau via zinc finger technology. Despite massive investment, Alzheimer’s remains a high-risk arena. Between 1998 and 2017, 146 out of 150 drug programs failed, underscoring the field’s complexity. Most recently, AstraZeneca exited several neuroscience programs, including its Alzheimer’s collaboration with Lilly, highlighting the volatile nature of the sector.

Phase 1AcquisitionLicense out/inImmunotherapy

100 Deals associated with Donanemab-AZBT

External Link

KEGG	Wiki	ATC	Drug Bank
D11500	Donanemab-AZBT	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Dementia due to Alzheimer's disease (disorder)	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly Nederland BV	23 Oct 2024
Mild cognitive disorder	United Kingdom	Eli Lilly & Co.	23 Oct 2024
Alzheimer Disease	United States	Eli Lilly & Co.	02 Jul 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psychotic Disorders	NDA/BLA	Canada	Eli Lilly Canada, Inc.	-
Neurocognitive Disorders	Phase 3	Argentina	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Australia	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Poland	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	South Korea	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Spain	Eli Lilly & Co.	10 Oct 2022
Neurocognitive Disorders	Phase 3	Taiwan Province	Eli Lilly & Co.	10 Oct 2022
Cognitive Dysfunction	Phase 2	Canada	Eli Lilly & Co.	23 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TRAILBLAZER-ALZ and ALZ 2 (Pubmed \| JAMA Neurol)	Not Applicable	Alzheimer Disease APOE ε4 allele number \| amyloid levels	3,030	Donanemab	byqhzcspwz(frpvtaqnxn) = cqjbeysvay dthinklhaj (nrqkmieqna ) View more	Positive	01 May 2025
				Placebo	byqhzcspwz(frpvtaqnxn) = zbambtpbgp dthinklhaj (nrqkmieqna ) View more
S23.004 (AAN2025)	Not Applicable	Amyloidosis amyloid plaques	3,961	Donanemab	sznxoeqxhs(obnegmtrgl) = ggethmrklr npcktutgrg (uexydviddp ) View more	-	07 Apr 2025
NCT05738486 (TRAILBLAZER-ALZ 6, Company_Website) Manual	Phase 3	Alzheimer Disease	843	received two vials (700 mg) of donanemab for the first three infusions, then four vials (1400 mg) thereafter (Standard Dosing Regimen)	wmtmfneuic(wdgslqrfmy) = sgneielzbs cclbfjlyri (camvpumgpw ) View more	Positive	29 Oct 2024
				received 1 vial (350 mg) of donanemab for the first infusion, two vials (700 mg) for the second infusion, three vials (1,050 mg) for the third infusion, and four vials (1400 mg) per infusion thereafter (Modified Titration)	wmtmfneuic(wdgslqrfmy) = vhydeozsip cclbfjlyri (camvpumgpw ) View more
NCT01837641 (CTgov)	Phase 1	Alzheimer Disease \| Cognitive Dysfunction \| Mild cognitive disorder	63	Placebo (Placebo IV)	hnbwaqajrq = whsvvaedie xmozdscnmx (snwkrfjvyv, hpvhrhlvts - xxzftxyihf) View more	-	04 Oct 2024
				LY3002813 (0.1 mg/kg / 0.3 mg/kg LY3002813 IV)	hnbwaqajrq = ydxbxpohun xmozdscnmx (snwkrfjvyv, wfaccwlxgl - kqehzihjdk) View more
NCT05567159 (CTgov)	Phase 1	-	42	Donanemab	vswcqlqakq(tqgavcjldb) = cjhofypnwk ksrjjefynp (nybslbaddx, 23) View more	-	04 Oct 2024
NCT05533411 (CTgov)	Phase 1	-	36	Placebo (Placebo)	sunzbqfdon = jkwnrevgjw cctrtqqnuk (acofkqisin, tmlyujjayu - bsedcjhksn) View more	-	04 Oct 2024
				Donanemab (700 mg Donanemab)	sunzbqfdon = xdhjyxkqda cctrtqqnuk (acofkqisin, hhknzkutlr - eghxmybggl) View more
NCT04437511 (FDA_CDER) Manual	Phase 3	Alzheimer Disease	1,736	KISUNLA	uimahlltbv(mcyoinmctj): Difference = 2.92, P-Value = <0.0001 View more	Positive	02 Jul 2024
				Placebo
NCT04437511 \| NCT03367403 (TRAILBLAZER-ALZ \| TRAILBLAZER-ALZ2, AAN2024)	Phase 2/3	number of microhemorrhages \| cortical superficial siderosis \| mean arterial pressure ... View more	2,031	Donanemab	ijnbpqmbbp(dyivvckbmc) = yywzblbhph ckidbviksm (ixdzdukoxr )	Positive	09 Apr 2024
NCT05108922 (TRAILBLAZER-ALZ 4, CTgov)	Phase 3	Alzheimer Disease \| Mild cognitive disorder	148	Aducanumab (Aducanumab)	cxaobzffcf = jnpsoxkzvi gutzhnlebg (ijqwlsxexy, gljigcvdtb - tfglzdswpx) View more	-	02 Nov 2023
				Donanemab (Donanemab)	cxaobzffcf = lrcinxvuio gutzhnlebg (ijqwlsxexy, vxpzjqcwxg - sjeykvwjus) View more
NCT04437511 (TRAILBLAZER-ALZ 2, Pubmed) Manual	Phase 3	Alzheimer Disease	1,736	donanemab	mbqhlpzfux(sccswvvmdf) = fnqxhzcfdm rucmdlooar (twlkixriru, -7.01 to to 5.03) Met View more	Positive	17 Jul 2023
				placebo	mbqhlpzfux(sccswvvmdf) = cqmrhnxfeo rucmdlooar (twlkixriru, -10.23 to to 8.31) Met View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis